Skip to content

Clinical trials

Completed Phase 1/2 Myelodysplastic Syndromes trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myelodysplastic Syndromes Phase: Phase 1/2 Status: Completed Clear all

115 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20013
20026
20035
20045
20054
200610
20074
20084
20099
20105
20114
20126
201313
20147
20155
20167
20172
20183
20191
20203
20211
20221

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed115

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center14
Fred Hutchinson Cancer Center7
Groupe Francophone des Myelodysplasies7
H. Lee Moffitt Cancer Center and Research Institute3
Masonic Cancer Center, University of Minnesota3
Memorial Sloan Kettering Cancer Center3
National Cancer Institute (NCI)3
Novartis Pharmaceuticals3
Singapore General Hospital3
Celgene2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myelodysplastic Syndromes115
Leukemia, Myeloid, Acute71
Leukemia42
Precursor Cell Lymphoblastic Leukemia-Lymphoma31
Leukemia, Myelomonocytic, Chronic23
Leukemia, Myelogenous, Chronic, BCR-ABL Positive22
Lymphoma, Non-Hodgkin22
Myeloproliferative Disorders21
Hodgkin Disease18
Multiple Myeloma18

Trials

Showing 1 to 25 of 115. Each trial links to its page on Pharma Observatory.

15 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.